It can be called good news for the adult population suffering from multiple myeloma or non-Hodgkin’s lymphomas.The FDA has approved a drug called Mozobil that promises to increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.
It can be added that multiple myeloma is the cancer of the plasma cell. The cell in the bone marrow produces antibodies to help fight infection and disease.
In two randomized clinical trials – one in patients with non-Hodgkin’s lymphoma, the other with multiple myeloma – Mozobil combined with G-CSF increased the number of stem cells available for collection and transplantation compared with patients receiving G-CSF alone.
Prior to receiving high-dose chemotherapy or radiation therapy, patients with these forms of cancer sometimes undergo a procedure known as apheresis in which blood stem cells are collected and stored for reinfusion after therapy. G-CSF is commonly administered to help release and collect stem cells from the bone marrow. Mozobil is an injectable drug that, when used in combination with G-CSF, boosts the number of stem cells released from the bone marrow into the blood stream.